Giant Cell Arteritis
Methodology & AI Transparency ⓘ
Giant Cell Arteritis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms.
- 2 Real-world patient consensus: Diagnostic registry M31.6: Giant Cell Arteritis is managed within Brain & Neurology.
- 3 Typical cash cost range: Workup highlights for Giant Cell Arteritis (M31.6): vascular stroke risk in Giant Cell Arteritis (M31.6: stratification).
- 4 Top reported side effects / signs: Objective lab/clinical target for Giant Cell Arteritis: Carotid Duplex / in Giant Cell Arteritis (M31.6: Cerebral Perfusion) (No hemodynamically significant stenosis (M31.6)) and HbA1c & Blood in Giant Cell Arteritis (M31.6: Pressure Neuro-Targets).
Ask our AI Specialists anything about Giant Cell Arteritis
What Is Giant Cell Arteritis?
Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica . Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in brain & neurology, Giant Cell Arteritis (M31.6) involves synaptic transmission alteration [Giant Cell Arteritis M31.6]. Cross-referenced with NIH MeSH (Giant Cell Arteritis), progression correlates with shifts in Carotid Duplex / in Giant Cell Arteritis (M31.6: Cerebral Perfusion) (No hemodynamically significant stenosis (M31.6)).
Common Symptoms & Clinical Signs
- • Pain and tenderness over the temples
- • Double vision or visual loss, dizziness
- • Presentation of Giant Cell Arteritis (M31.6): episodic vertigo, imbalance, in Giant Cell Arteritis (M31.6: coordination drift, or)
- • Secondary Giant Cell Arteritis clinical sign: numbness, paresthesia, or in Giant Cell Arteritis (M31.6: visual field/speech changes)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Giant Cell Arteritis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M31.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Carotid Duplex / in Giant Cell Arteritis (M31.6: Cerebral Perfusion) | No hemodynamically significant stenosis (M31.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Giant Cell Arteritis (M31.6: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (M31.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Giant Cell Arteritis (M31.6: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (M31.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Giant Cell Arteritis
Treatment selection for Giant Cell Arteritis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Giant Cell Arteritis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on CONCERTO: A randomized, compared against a dummy pill (placebo) trial of oral: What a 727-Participant Study Found Laquinimod 0.6 mg demonstrated only nominally significant effects on clinical relapses and magnetic resonance imaging (MRI) outcomes and was generally well tolerated. Multiple sclerosis (Houndmills, Basingstoke, England) • 2022-04-15 • Phase III Randomized Trial | N = 727 | 93/100 | PMID 34378456 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase 3 randomized, gold-standard blind, compared against a dummy pill Owing to the small sample size due to the early termination, it is difficult to draw clear conclusions from this study. Arthritis research & therapy • 2023-10-16 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37840134 ↗ |
| Can This Approach Help? Inside the Latest Research on Secukinumab for Giant Cell Sustained full symptom relief at week 52 did not differ significantly between patients with GCA randomly assigned to receive SEC-300 with a 26-week GC taper versus placebo with a 52-week GC taper. NEJM evidence • 2026-07-15 • Phase III Randomized Trial | N = 140 | 88/100 | PMID 42234457 ↗ |
| Can This Approach Help? Inside the Latest Research on Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial The responder definitions were at least a 3-point improvement for PROMIS-PF, a 10% improvement for active ROM, and a 2-point improvement for the Worst Stiffness NRS. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation • 2026-02-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41621028 ↗ |
| Can This Approach Help? Inside the Latest Research on Four months of treatment with anakinra combined with glucocorticoids for giant Although prematurely discontinued, this study does not support the use of 4 months of treatment with anakinra combined with GCs to reduce the risk of relapse or GC exposure. Arthritis research & therapy • 2025-06-07 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40483523 ↗ |
Giant Cell Arteritis Patient Community & “People Like Me” Threads
Filter Giant Cell Arteritis community threads and patient logs by age, biological sex, dosage, and treatment duration.